Top Markets
#1 Orochi Network Orochi Network +71.79%
#2 Bitway Bitway +26.98%
#3 Audiera Audiera +24.63%
#4 RSK Infrastructure Framework RSK Infrastructure Framework +18.60%
#5 Pharos Pharos +15.97%
#6 SOON SOON +15.75%
#7 Cheems Token Cheems Token +14.21%
#8 Taiko Taiko +13.85%
#9 Manadia Manadia +13.47%
#10 ROLL ROLL +13.27%
Coin of the day
Orochi Network Orochi Network
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Kedudukan dalam Saham #72
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Harga Saham
$50.95
Modal Pasaran
$226.41B
Perubahan (1 hari)
2.58%
Perubahan (1 tahun)
-26.16%
Negara
DK
Perdagangan Novo Nordisk A/S (NVO)

Kategori

Healthcare
Nisbah P/E bagi Novo Nordisk A/S (NVO)
Nisbah P/E pada July 2026 TTM: 11.65
Menurut laporan kewangan dan harga saham terkini Novo Nordisk A/S, nisbah P/E semasa (TTM) ialah 11.65. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 27.53.
Sejarah nisbah P/E bagi Novo Nordisk A/S dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 11.65 -17.43%
2025 14.11 -48.75%
2024 27.53 -26.39%
2023 37.40 -2.28%
2022 38.27 8.25%
2021 35.35 49.61%
2020 23.63 0.26%
2019 23.57 23.65%
2018 19.06 -12.01%
2017 21.66 27.49%
2016 16.99 -42.39%
2015 29.49 14.43%
2014 25.77 21.85%
2013 21.15 -11.44%
2012 23.88 9.42%
2011 21.83 -13.90%
2010 25.35 37.23%
2009 18.48 6.65%
2008 17.32 -27.90%
2007 24.03 1.28%
2006 23.72 19.31%
2005 19.88 -0.71%
2004 20.02 18.71%
2003 16.87 -2.64%
2002 17.33 -43.27%
2001 30.54 -2.36%
2000 31.28 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.00 140.34%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 15.43 32.41%
US
UCB SA UCB SA
UCB SA
UCB.BR
 28.35 143.36%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 48.77 318.63%
NL
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
ALNY.US
 64.51 453.68%
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.